A non-producing strain, the so-called strain RNBC-5-51 SANK 60198, was isolated during a screening program of strain improvement in the milbemycin production. Strain RNBC-5-51 indicated almost the same characteristics as those in the parent strain, that is, the abundant spore formation on agar media and the good growth in liquid media. But it does not produce any kind of milbemycins. In addition, strain RNBC-5-51 accumulated precursor-like compounds of milbemycin-polyketide, the production of which were inhibited by the addition of cerulenin. In the bioconversion experiments, strain RNBC-5-51 converted milbemycin β6 and A4 to milbemycin α14, and milbemycin β7 and A3 to milbemycin α11, respectively. This strain also converted milbemycin D and avermectin Bla, to 26-(3-methyl-2-butenoyloxy)milbemycin D and 26-(3-methyl-2-butenoyloxy)avermectin Bla, respectively. These results suggest that milbemycin α11 is biosynthesized through the same route as milbemycin α14, and the mutated step in strain RNBC-5-51 might be in the polyketide synthetic pathway of milbemycins. Strain RNBC-5-51 loses the ability for de novo synthesis of milbemycins, but it retains the ability to bioconvert the milbemycin skeleton. This strain might be useful for C-26 modification of milbemycin-related compounds.
在米尔贝霉素生产的菌株改良筛选计划中,分离出了一株不生产米尔贝霉素的菌株,即所谓的 R
NBC-5-51
SANK 60198 菌株。菌株 R
NBC-5-51 与母本菌株的特征几乎相同,即在
琼脂培养基上有大量孢子形成,在液体
培养基中生长良好。但它不产生任何种类的米贝菌素。此外,菌株 R
NBC-5-51 积累了类似于米尔贝菌素聚酮的前体化合物,而加入神经
鞘氨醇可抑制其产生。 在
生物转化实验中,菌株 R
NBC-5-51 分别将米尔贝霉素 β6 和 A4 转化为米尔贝霉素 α14,将米尔贝霉素 β7 和 A3 转化为米尔贝霉素 α11。该菌株还能将小米霉素 D 和
阿维菌素 Bla 分别转化为 26-(3-甲基-
2-丁烯酰氧基)小米霉素 D 和 26-(3-甲基-
2-丁烯酰氧基)
阿维菌素 Bla。 这些结果表明,米尔贝霉素α11与米尔贝霉素α14的
生物合成途径相同,菌株R
NBC-51的突变步骤可能是米尔贝霉素的多酮合成途径。菌株 R
NBC-5-51 失去了从头合成米尔贝霉素的能力,但保留了
生物转化米尔贝霉素骨架的能力。该菌株可能有助于米尔贝霉素相关化合物的 C-26 改造。